tailieunhanh - báo cáo khoa học: "Metastatic collecting duct carcinoma of the kidney treated with sunitinib"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Metastatic collecting duct carcinoma of the kidney treated with sunitinib | Tazi et al. World Journal of Surgical Oncology 2011 9 73 http content 9 1 73 7 2 WORLD JOURNAL OF SURGICAL ONCOLOGY CASE REPORT Open Access Metastatic collecting duct carcinoma of the kidney treated with sunitinib 1 1 2 2 1 1 El Mehdi Tazi Ismail Essadi Mohamed Fadl Tazi Youness Ahellal Hind Mrabti and Hassan Errihani Abstract Collecting duct carcinoma CDC of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor sunitinib achieving a partial response in both lung and skeletal metastases. To our knowledge this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors particularly sunitinib in the management of metastatic CDC. Keywords Collecting duct carcinoma Sunitinib Metastasis Introduction Collecting duct carcinoma CDC of the kidney also known as Bellini duct carcinoma is a rare variant of renal cell carcinoma RCC arising from the epithelium of the distal collecting ducts it accounts for 2 of all RCCs 1 . Clinically CDC is characterized by an extremely aggressive phenotype accompanying metastatic diseases at presentation in most reported cases the prognosis ofCDC is therefore poor with approximately 70 of patients dying of disease progression within 2 years after diagnosis. In fact several systemic therapies including cytokine therapy and cytotoxic chemotherapy have failed to achieve favorable response to metastatic CDC except for very limited cases 2-7 . Sunitinib is an orally available inhibitor of multiple receptor tyrosine kinases including vascular endothelial growth factor receptor platelet-derived growth factor receptor and others with direct antitumor and antiangio-genic activity.